oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Connective tissue is the structure that holds the body together and is composed largely of collagen and elastin.
Connective tissue disorders are classified into a number of groups. The significance of pregnancy varies considerably according to the type of the disease:
- Hereditary connective tissue disorders (HCTDs) includes such diseases as Ehlers-Danlos syndrome, Marfan's syndrome and pseudoxanthoma elasticum (PXE).
- Mixed connective tissue disease (MCTD):
- This was first described in 1972, and was considered as an overlap or combination of systemic lupus erythematosus (SLE), scleroderma, and polymyositis.
- Patients have features of each of these three diseases. Typically, they also have very high titres of antinuclear antibodies (ANAs) and antibodies to ribonucleoprotein (anti-RNP).
- Often the disease evolves to become dominated by features of one of the three component illnesses, most commonly the scleroderma features.
- Unclassified connective tissue disorders (UCTDs) means that there may be some features of connective tissue disorders such as ANA or perhaps features of three different diseases and it is not possible to classify to a specific disease. Follow-up of UCTD shows conversion to a specific disease in about 20%.
The hereditary forms tend to manifest fairly early in life. They are not often apparent at birth but are usually diagnosed before the advent of reproduction. The autoimmune forms tend to present after the reproductive years but it is not at all uncommon for them to present before middle age. Reproductive problems may be the presenting feature.
- The hereditary connective tissue diseases (HCTDs) are usually inherited in a typical Mendelian form as autosomal dominant. Males and females are equally affected.
- The autoimmune diseases are acquired rather than inherited but they do tend to run in families. The exact aetiology is uncertain but, if there is an external trigger, it would appear that a genetic predisposition is involved.
- The conditions are more common in women.
Pregnancy in hereditary connective tissue disorders
- For the hereditary forms, genetic counselling is important, ideally before the woman becomes pregnant.
The risk varies considerably according to the type of the condition:
- Obstetric complications include risk of uterine rupture during labour, damage to the vagina and perineum, bleeding and rupture of blood vessels and the colon during the puerperium.
- In type IV there is a risk for severe bleeding and vessel rupture associated with pregnancy.
- In type II a Shirodkar's suture may be required to treat cervical incompetence.
- Generally Ehlers-Danlos syndrome is well tolerated in pregnancy except in type IV.
- The major risk is aortic dissection in pregnancy. Family history may indicate the level of this risk but echocardiography to assess the aortic root in pregnancy should be used.
- Aortic dissection is not the only problem and a multidisciplinary approach is recommended.
- Surgery may be required before embarking on pregnancy. Aortic repair can be performed during pregnancy.
- Betablockers may be protective although they are associated with the risk of low birthweight babies.
Pseudoxanthoma elasticum (PXE)
- This disease is characterised by degeneration of elastic tissue. Clinically, its effects are most readily noted in the skin, retina, blood vessels, and myocardium.
- It is not associated with particularly increased fetal loss or adverse outcomes. A few pregnancies are associated with worsening of skin manifestations.
- The incidence of gastric bleeding is probably higher than in the unaffected population.
- Retinal complications are uncommon.
Pregnancy in autoimmune connective tissue disorders
As well as any effects caused directly by the connective tissue disorder, the woman may be taking drugs for the condition and these may be teratogenic, eg methotrexate which induces abortion. The relative risks and benefits of the various drugs in pregnancy need to be carefully weighed.
- The risk of fetal loss is much higher than in the general population and this is particularly marked in those with systemic lupus erythematosus (SLE) or a component of the disease in their connective tissue disease disorder.
- The highest risk of all comes with those with antiphospholipid antibodies, and the problem of pregnancy is discussed in the separate Antiphospholipid Syndrome article. Not only is there a high incidence of miscarriage in the first trimester, but there is a significant risk of intrauterine death in the second and third trimesters.
In women with SLE the acronym 'PATH' represents:
- P roteinuria
- A ntiphospholipid syndrome
- T hrombocytopenia
- H ypertension early in pregnancy
All of these are serious risk factors for adverse pregnancy outcomes.
Pregnancy in patients with systemic lupus erythematosus
Fertility is normal and pregnancy is safe in mild or stable lupus. In severe lupus, pregnancy should be delayed until the disease is better controlled.
Effects on fertility
- Women with rheumatoid arthritis (RA) have fewer children than average but this appears to be a conscious decision related to the difficulty of rearing children, with the limitations of the disease, rather than problems of fecundity.
- However, a survey of American women with systemic lupus erythematosus (SLE) and RA found that hypertensive disorders of pregnancy occurred in 23.2% of those with SLE and 11.1% of those with RA compared with 7.8% of the general population.
- They tended to have more Caesarean sections and longer stays in hospital.
- They also tended to be older than the general population having babies but this did not account for the difference.
- In women with stable SLE, the use of oral contraceptives does not increase the risk of flare-up.
Further reading & references
- Hildebrand BA et al; Undifferentiated Connective-tissue Diseases, eMedicine, Jul 2009; Diseases discussed but no mention of pregnancy
- Petrozza JC et al; Recurrent Early Pregnancy Loss, eMedicine, Jul 2010; Contains a section on autoimmune abnormalities
- Sharp GC, Irvin WS, Tan EM, et al; Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148-59.
- Erez Y, Ezra Y, Rojansky N; Ehlers-Danlos type IV in pregnancy. A case report and a literature review. Fetal Diagn Ther. 2008;23(1):7-9. Epub 2007 Oct 9.
- Combeer EL, Combeer AD; A rare cause of maternal death: liver and inferior vena cava rupture due to Eur J Anaesthesiol. 2008 Sep;25(9):765-7. Epub 2008 Apr 10.
- Ploeckinger B, Ulm MR, Chalubinski K; Ehlers-Danlos syndrome type II in pregnancy. Am J Perinatol. 1997 Feb;14(2):99-101.
- Lind J, Wallenburg HC; Pregnancy and the Ehlers-Danlos syndrome: a retrospective study in a Dutch population. Acta Obstet Gynecol Scand. 2002 Apr;81(4):293-300.
- Bowater SE, Thorne SA; Management of pregnancy in women with acquired and congenital heart disease. Postgrad Med J. 2010 Feb;86(1012):100-5.
- Montan S; Drugs used in hypertensive diseases in pregnancy. Curr Opin Obstet Gynecol. 2004 Apr;16(2):111-5.; Curr Opin Obstet Gynecol. 2004 Apr;16(2):111-5.
- Bercovitch L, Leroux T, Terry S, et al; Pregnancy and obstetrical outcomes in pseudoxanthoma elasticum. Br J Dermatol. 2004 Nov;151(5):1011-8.
- Clowse ME, Magder LS, Witter F, et al; Early risk factors for pregnancy loss in lupus. Obstet Gynecol. 2006 Feb;107(2 Pt 1):293-9.
- Katz PP; Childbearing decisions and family size among women with rheumatoid arthritis. Arthritis Rheum. 2006 Apr 15;55(2):217-23.
- Chakravarty EF, Nelson L, Krishnan E; Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):899-907.
- Petri M, Kim MY, Kalunian KC, et al; Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Colin Tidy
Dr Hayley Willacy